Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
Bluejay Diagnostics develops the Symphony Suite, a near-patient diagnostic testing system that delivers medical test results in about 20 minutes, faster than traditional clinical chemistry labs. The products target healthcare settings inside and outside the lab to reduce wait times and support faster clinical decisions.
0 investors
0 investors
0 investors
0 investors
Bone Biologics develops a medical device combining a recombinant human protein called NELL-1 with demineralized bone matrix for use in spinal fusion and other orthopedic procedures to promote controlled bone regeneration. The company is conducting clinical trials of its lead product candidate, NB1, in lumbar spinal fusion applications and is pursuing FDA approval before commercialization in the United States.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Bot Image develops ProstatID, an AI-based software that analyzes prostate MRI scans to detect and highlight suspect lesions, helping urologists and radiologists improve diagnostic accuracy for prostate cancer. The tool supports clinical diagnosis and guides therapeutic decisions, often confirmed by biopsy.
0 investors
0 investors
0 investors
BoundlessDx (Boundless Diagnostics) develops portable, handheld point-of-care diagnostic devices that deliver rapid results from small fluid samples for veterinary use. Its tests, including inflammation and multi-analyte panels for dogs, cats, and horses, serve animal health practitioners in the veterinary diagnostics market.
0 investors
0 investors
0 investors
0 investors
0 investors
BrainXell is a company focused on advancing research and improving patient outcomes through scientific work and services. Its stated mission centers on neuroscience-related research, associated with Dr. Su-Chun Zhang.
0 investors
Branch Therapeutics develops first-in-class, orally available dual-kinase inhibitors designed to modulate WNT/β-catenin and PI3Kα signaling to target cancer stem cells and treatment resistance in solid tumors. The company pairs its therapies with a precision biomarker strategy aimed at safer, longer-lasting responses to cancer treatment.
0 investors
0 investors
0 investors
0 investors
0 investors